Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02231723 · ClinicalTrials.gov registry record · Phase 1
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer
A Phase 1 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 1
- Development phase
- 139
- Enrollment target
NCT02231723 is a Phase 1 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 139 participants.
The verdict
NCT02231723, a Phase 1 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 139 participants
- Enrollment target
Study Summary
This is an open label, multi-center, multi-arm, dose-escalation study of BBI608 administered in combination with Gemcitabine and nab-Paclitaxel, mFOLFIRINOX, FOLFIRI, or MM-398 with 5-FU and leucovorin.
Interventions
- DRUG Leucovorin
- DRUG Oxaliplatin
- DRUG Gemcitabine
- DRUG Nab-paclitaxel
- DRUG BBI608
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2014-08 |
| Est. Completion | 2020-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02231723
The ClinicalTrials.gov registry entry for NCT02231723 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 139 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Leucovorin is the first listed.
NCT02231723 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02231723 about?
NCT02231723 is a clinical study titled "A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer". This is an open label, multi-center, multi-arm, dose-escalation study of BBI608 administered in combination with Gemcitabine and nab-Paclitaxel, mFOLFIRINOX, FOLFIRI, or MM-398 with 5-FU and leucovorin.
What is the current status of trial NCT02231723?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 139 participants. The study started on 2014-08. Estimated completion is 2020-06.
What interventions are being tested in trial NCT02231723?
The interventions under investigation include: Leucovorin (DRUG), Oxaliplatin (DRUG), Gemcitabine (DRUG), Nab-paclitaxel (DRUG), BBI608 (DRUG).
Who is sponsoring clinical trial NCT02231723?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.